Shannon McCall

Overview:

As Vice Chair for Translational Research in the Department of Pathology, I am involved in numerous translational cancer research projects that rely on the study of human biological samples. I am the director of the Duke BioRepository & Precision Pathology Center (Duke BRPC), a shared resource of the School of Medicine and the Duke Cancer Institute. I serve as the PI for the National Cancer Institute's Cooperative Human Tissue Network Southern Division (a five-year UM1 grant), which lives in the Duke BRPC. My own area of research interest is gastrointestinal tract metaplasias and their relationship to carcinogenesis, particularly in the upper GI tract.

Positions:

Associate Professor of Pathology

Pathology

School of Medicine

Associate Professor in Surgery

Surgery, Surgical Sciences

School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute

School of Medicine

Education:

B.S. 1996

North Carolina State University

M.D. 2000

Duke University

Anatomic and Clinical Pathology, American Board of Pathology (ABPath)

American Board of Pathology

Clinical Informatics, American Board of Pathology (ABPath)

American Board of Pathology

Resident, Pathology

Duke University

Chief Resident, Pathology

Duke University

Grants:

Mutation analysis of pap smear samples and associated tissues for ovarian cancer diagnostics

Administered By

Pathology

Awarded By

Genendeavor LLC

Role

Principal Investigator

Start Date

October 12, 2017

End Date

July 17, 2020

Cooperative Human Tissue Network Support through Duke's BioRepository & Precision Pathology Center

Administered By

Pathology

Awarded By

National Institutes of Health

Role

Principal Investigator

Start Date

May 02, 2019

End Date

April 30, 2024

The genetics of hepatosplenic T cell lymphoma

Administered By

Medicine, Hematologic Malignancies and Cellular Therapy

Awarded By

National Institutes of Health

Role

Co Investigator

Start Date

April 01, 2015

End Date

March 31, 2017

Empowering Duke's Precision Pathology Center with Quantitative Image Analysis to Support Discovery, Diagnostic Assay Development, and Immune Cell Monitoring

Administered By

Pathology

Awarded By

North Carolina Biotechnology Center

Role

Principal Investigator

Start Date

February 01, 2018

End Date

January 31, 2019

Lung Squamous Cell Carcinoma: Validation of Molecular Signatures of Prognosis

Awarded By

University of Colorado - Denver

Role

Pathologist

Start Date

July 09, 2012

End Date

May 30, 2017

Publications:

Supplementary Table 1 from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer

Patient demographic are described in supplementary Table 1

Authors

Somarelli, JA; Roghani, RS; Moghaddam, AS; Thomas, BC; Rupprecht, G; Ware, KE; Altunel, E; Mantyh, JB; Kim, SY; McCall, SJ; Shen, X; Mantyh, CR; Hsu, DS

MLA Citation

Somarelli, Jason A., et al. Supplementary Table 1 from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer. 3 Apr. 2023. Crossref, doi:10.1158/1535-7163.22521145.

URI

https://scholars.duke.edu/individual/pub1571796

Source

crossref

Published Date

2023

DOI

10.1158/1535-7163.22521145

Supplementary Data from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer

Supplementary Figures

Authors

Somarelli, JA; Roghani, RS; Moghaddam, AS; Thomas, BC; Rupprecht, G; Ware, KE; Altunel, E; Mantyh, JB; Kim, SY; McCall, SJ; Shen, X; Mantyh, CR; Hsu, DS

MLA Citation

Somarelli, Jason A., et al. Supplementary Data from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer. 3 Apr. 2023. Crossref, doi:10.1158/1535-7163.22521148.

URI

https://scholars.duke.edu/individual/pub1571797

Source

crossref

Published Date

2023

DOI

10.1158/1535-7163.22521148

Supplementary Data from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer

Supplementary Figures

Authors

Somarelli, JA; Roghani, RS; Moghaddam, AS; Thomas, BC; Rupprecht, G; Ware, KE; Altunel, E; Mantyh, JB; Kim, SY; McCall, SJ; Shen, X; Mantyh, CR; Hsu, DS

MLA Citation

URI

https://scholars.duke.edu/individual/pub1571798

Source

crossref

Published Date

2023

DOI

10.1158/1535-7163.22521148.v1

Supplementary Table 1 from A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer

Patient demographic are described in supplementary Table 1

Authors

Somarelli, JA; Roghani, RS; Moghaddam, AS; Thomas, BC; Rupprecht, G; Ware, KE; Altunel, E; Mantyh, JB; Kim, SY; McCall, SJ; Shen, X; Mantyh, CR; Hsu, DS

MLA Citation

URI

https://scholars.duke.edu/individual/pub1571799

Source

crossref

Published Date

2023

DOI

10.1158/1535-7163.22521145.v1

Erratum to "Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy" [Eur Urol 2022;81(5):446-55].

Authors

Cheng, Q; Butler, W; Zhou, Y; Zhang, H; Tang, L; Perkinson, K; Chen, X; Jiang, XS; McCall, SJ; Inman, BA; Huang, J

MLA Citation

Cheng, Qing, et al. “Erratum to "Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy" [Eur Urol 2022;81(5):446-55].” Eur Urol, Apr. 2023. Pubmed, doi:10.1016/j.eururo.2023.03.019.

URI

https://scholars.duke.edu/individual/pub1572048

PMID

37012130

Source

pubmed

Published In

Eur Urol

Published Date

2023

DOI

10.1016/j.eururo.2023.03.019

Research Areas:

Ampulla of Vater

Apoptosis

Bevacizumab

Bile Ducts

Biological Markers

Biopsy

Biopsy, Needle

Cell Differentiation

Cell Line

Cell Nucleus

Cell Proliferation

Cell Survival

Cells, Cultured

Colorectal Neoplasms

Colorectal Neoplasms, Hereditary Nonpolyposis

Cytochrome P-450 CYP2E1

Endocytosis

Epithelial Cells

Epithelial-Mesenchymal Transition

Gene Deletion

Gene Expression Profiling

Gene Expression Regulation

Gene Expression Regulation, Developmental

Gene Expression Regulation, Neoplastic

Genetic Predisposition to Disease

Hedgehog Proteins

Homeodomain Proteins

Humans

Hydroxyproline

Immunohistochemistry

Kruppel-Like Transcription Factors

Lasers

Mesenchymal Stromal Cells

Mesoderm

Microdissection

Mutation

Nuclear Proteins

Oligonucleotides, Antisense

Oligoribonucleotides, Antisense

Oncogenes

Organoplatinum Compounds

Pancreaticoduodenectomy

Pancreatitis

Pilot Projects

Prognosis

Protein Isoforms

Proteome

Proto-Oncogene Proteins

Proto-Oncogene Proteins B-raf

Pyrimidines

RNA, Messenger

Receptors, Cell Surface

Recombinant Proteins

Reverse Transcriptase Polymerase Chain Reaction

Signal Transduction

Stromal Cells

Thiazoles

Tissue Donors

Tumor Markers, Biological

Tumor Necrosis Factor-alpha

Wnt Proteins

Xenograft Model Antitumor Assays

ras Proteins

Associate Professor of Pathology

Contact:

Profile

https://scholars.duke.edu/person/shannon.mccall

Dept of Pathology Box 3712, Room 309 Davison Building, Durham, NC 27710

Duke Box 3712, Room 309 Davison Bldg, Durham, NC 27710